肺纤维化生物标记市场- 依测试类型（血液检查、影像学检查、肺活检）、适应症（特发性肺纤维化、尘肺病、结节病）、最终用户（医院、诊断实验室） - 全球预测2024 - 2032

由于该领域的研究和开发不断增加，2024 年至 2032 年间，全球肺纤维化生物标记市场规模的复合年增长率将达到 4.4%。随着对肺纤维化的了解加深，对能够准确诊断疾病、监测其进展和预测治疗结果的生物标记的需求不断增长。例如，2023 年 11 月，基因泰克公司的研究人员在一群科学家的带领下，努力寻找特发性肺纤维化 (IPF)（一种严重肺部疾病）的生物标记。他们的重点在于探索生物活性脂质是否具有预测 IPF 进展的潜力。基因泰克公司的资深科学家 Margaret Neighbors 透露，他们最初的研究工作集中在慢性阻塞性肺病（COPD）。

先进的生物标记物能够实现早期检测和个人化治疗策略，从而改善患者护理和预后。此外，正在进行的研究工作正在发现具有潜在诊断和预后效用的新型生物标记物，从而推动市场成长。随着全球肺纤维化负担的加重以及对精准医疗的日益重视，对可靠生物标记的需求预计将继续增长，从而塑造肺纤维化生物标记市场的未来。

整个肺纤维化生物标记行业根据测试类型、适应症、最终用户和地区进行分类。

血液检测领域将在 2024 年至 2032 年期间经历突破性发展。随着研究不断发现与疾病严重程度和预后相关的新型血液生物标记物，对可靠血液检测的需求正在增加。医疗保健提供者越来越多地将基于血液的生物标记测试纳入其诊断演算法中，推动了肺纤维化生物标记市场的扩大，并为与这种使人衰弱的肺部疾病作斗争的患者带来改善结果的希望。

The pulmonary fibrosis biomarkers share from the drug induced pulmonary fibrosis segment will register a noteworthy CAGR from 2024 to 2032. As adverse drug reactions continue to pose a significant concern, there is a pressing need for biomarkers that can accurately detect and monitor drug-induced lung受伤.这些生物标记在识别高风险患者、实现早期介入和促进个人化治疗方法方面发挥着至关重要的作用。随着旨在识别与药物引起的肺纤维化相关的特定生物标记的持续研究工作，对创新诊断工具的需求不断增加，推动肺纤维化生物标记市场的成长并改善患者护理结果。

欧洲肺纤维化生物标记市场将在2024年至2032年呈现出值得称讚的复合年增长率。准确检测和监测疾病进展的生物标记的需求不断增加。欧洲监管机构也鼓励开发和采用基于生物标记的诊断工具，进一步推动市场成长。因此，欧洲的肺纤维化生物标记市场正在显着扩张，为製造商和研究人员满足该地区不断变化的医疗保健需求提供了有利可图的机会。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 肺纤维化盛行率上升
    • 生物标记发现技术不断进步
    • 不断增加的政府措施和政策
    • 增加生物标誌物的使用
  • 产业陷阱与挑战
    • 与生物标记测试和诊断相关的高成本
    • 严格的监管场景
• 成长潜力分析
• 监管环境
• 技术景观
• 波特的分析
• PESTEL分析
• 未来市场趋势

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵

第 5 章：市场估计与预测：按测试类型，2018 年 - 2032 年

• 主要趋势
• 验血
  • C反应蛋白测试
  • 抗体检测试剂盒
    • 抗核抗体（ANA）测试
    • 抗CCP抗体检测
  • ESR 测试和 CBC
  • 肺功能检查
  • 影像学检查
    • X 光扫描
    • HRCT 扫描
  • 肺活检
  • 其他测试类型

第 6 章：市场估计与预测：按指标划分，2018 年 - 2032 年

• 主要趋势
• 特发性肺纤维化（IPF）
• 类风湿性关节炎间质性肺病 (RA-ILD)
• 药物性肺纤维化
• COVID-19相关的肺纤维化
• 尘肺
• 结节病
• 其他适应症

第 7 章：市场估计与预测：按最终用户划分，2018 年 - 2032 年

• 主要趋势
• 医院
• 专科诊所
• 诊断实验室
• 研究与学术机构
• 其他最终用户

第 8 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Biocartis NV
• Biogen Inc.
• Bristol-Myers Squibb Company
• F. Hoffman-La Roche Ltd
• Galapagos NV
• Lung Therapeutics, Inc.
• Myriad Genetics, Inc.
• OptiKira LLC
• Respivant Sciences GmbH
• Veracyte, Inc.

Global Pulmonary Fibrosis Biomarkers Market Size will witness 4.4% CAGR between 2024 and 2032 due to rising research and developments in the field. As understanding of pulmonary fibrosis deepens, there is a growing need for biomarkers that can accurately diagnose the disease, monitor its progression, and predict treatment outcomes. For instance, in November 2023, researchers at Genentech Inc., spearheaded by a team of scientists, were endeavoring to identify biomarkers for idiopathic pulmonary fibrosis (IPF), a severe lung disease. Their focus lies in exploring whether bioactive lipid species hold potential in predicting the progression of IPF. Margaret Neighbors, a senior scientist at Genentech, revealed that their initial research efforts were centered on chronic obstructive pulmonary disease (COPD).

Advanced biomarkers enable early detection and personalized treatment strategies, improving patient care and prognosis. Moreover, ongoing research efforts are uncovering novel biomarkers with potential diagnostic and prognostic utility, driving market growth. With the global burden of pulmonary fibrosis on the rise and a growing emphasis on precision medicine, the demand for reliable biomarkers is expected to continue growing, shaping the future of the Pulmonary Fibrosis Biomarkers Market.

The overall Pulmonary Fibrosis Biomarkers Industry is classified based on the test type, indication, end-user, and region.

The blood test segment will undergo groundbreaking development from 2024 to 2032. Blood-based biomarkers offer a non-invasive and accessible means of assessing pulmonary fibrosis progression, aiding in treatment decision-making and patient management. As research continues to identify novel blood biomarkers associated with disease severity and prognosis, the demand for reliable blood tests is escalating. Healthcare providers are increasingly incorporating blood-based biomarker testing into their diagnostic algorithms, fueling the expansion of the Pulmonary Fibrosis Biomarkers Market and offering hope for improved outcomes for patients battling this debilitating lung condition.

The pulmonary fibrosis biomarkers share from the drug induced pulmonary fibrosis segment will register a noteworthy CAGR from 2024 to 2032. As adverse drug reactions continue to pose a significant concern, there is a pressing need for biomarkers that can accurately detect and monitor drug-induced lung injury. These biomarkers play a crucial role in identifying patients at risk, enabling early intervention, and facilitating personalized treatment approaches. With ongoing research efforts aimed at identifying specific biomarkers associated with drug-induced pulmonary fibrosis, the demand for innovative diagnostic tools is on the rise, driving growth in the Pulmonary Fibrosis Biomarkers Market and improving patient care outcomes.

Europe pulmonary fibrosis biomarkers market will showcase a commendable CAGR from 2024 to 2032. With a rising prevalence of pulmonary fibrosis cases and a need for early diagnosis and targeted treatment, there is a heightened demand for biomarkers that can accurately detect and monitor the disease progression. European regulatory bodies are also encouraging the development and adoption of biomarker-based diagnostic tools, further fueling market growth. As a result, the Pulmonary Fibrosis Biomarkers Market in Europe is witnessing significant expansion, presenting lucrative opportunities for manufacturers and researchers to address the region's evolving healthcare needs.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data sources
  • 1.5.1 Primary
  • 1.5.2 Secondary
    • 1.5.2.1 Paid sources
    • 1.5.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of pulmonary fibrosis
    • 3.2.1.2 Increasing advancements in biomarker discovery technologies
    • 3.2.1.3 Rising government initiatives and policies
    • 3.2.1.4 Increasing use of biomarkers
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost associated with biomarker tests and diagnostics
    • 3.2.2.2 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis
• 3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix

Chapter 5 Market Estimates and Forecast, By Test Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Blood test
  • 5.2.1 C-reactive protein test
  • 5.2.2 Antibody testing kits
    • 5.2.2.1 Antinuclear antibodies (ANA) test
    • 5.2.2.2 Anti-CCP antibody test
  • 5.2.3 ESR test and CBC
  • 5.2.4 Pulmonary function test
  • 5.2.5 Imaging test
    • 5.2.5.1 X-rays scans
    • 5.2.5.2 HRCT scans
  • 5.2.6 Lung biopsy
  • 5.2.7 Other test types

Chapter 6 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Idiopathic pulmonary fibrosis (IPF)
• 6.3 Rheumatoid arthritis interstitial lung disease (RA-ILD)
• 6.4 Drug-induced pulmonary fibrosis
• 6.5 COVID-19-related pulmonary fibrosis
• 6.6 Pneumoconiosis
• 6.7 Sarcoidosis
• 6.8 Other indications

Chapter 7 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Specialty clinics
• 7.4 Diagnostic laboratories
• 7.5 Research & academic institutes
• 7.6 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Biocartis NV
• 9.2 Biogen Inc.
• 9.3 Bristol-Myers Squibb Company
• 9.4 F. Hoffman-La Roche Ltd
• 9.5 Galapagos NV
• 9.6 Lung Therapeutics, Inc.
• 9.7 Myriad Genetics, Inc.
• 9.8 OptiKira LLC
• 9.9 Respivant Sciences GmbH
• 9.10 Veracyte, Inc.